A Look at Medtronic’s Valuation Following FDA Approval of Altaviva Urinary Incontinence Device

Medtronic (NYSE:MDT) saw a spark in user interest this week after receiving FDA approval for its Altaviva device, a minimally invasive implantable designed to treat urge urinary incontinence. The device aims to fill a major gap in therapy options.

See our latest analysis for Medtronic.

Medtronic’s recent FDA approval for the Altaviva device follows a series of notable milestones, including a €1.5 billion bond issuance to extend its debt maturity and continued expansion in digital health. Despite these events, the stock has delivered a steady 1-year total shareholder return of 12.4%, reflecting building momentum as the company sharpens its focus on innovation and operational strength for the long run.

If Medtronic’s latest therapy breakthrough has you watching the medtech space, it’s a smart time to explore other healthcare stocks making waves. See the full list here: See the full list for free.

Yet with strong performance and growing optimism around its pipeline, does Medtronic still offer real upside at today’s price, or is the market already factoring in all the future growth that investors expect?

Most Popular Narrative: 3.2% Undervalued

Medtronic finished the week with a last close of $95.48, just below the narrative’s fair value of $98.63, according to the most popular view among analysts. With sentiment swirling around new innovations and operational pivots, there is more beneath the surface supporting this price.

Medtronic's investments and breakthroughs in digital health technologies, robotics (Hugo), next-generation sensors, and AI-enabled ecosystems (e.g., spine AiBLE, advanced neuromodulation) align with industry-wide digital transformation and minimally invasive trends. These platforms are set to expand procedure volumes and capture market share, supporting future top-line growth and higher-margin revenue streams.

Read the complete narrative.

Curious to uncover what could power the next leg up? The narrative hinges on the belief that Medtronic’s innovation pipeline and future profitability could put it on a whole new playing field. The real story is in the bold assumptions and forecasts analysts are using. Are you ready to discover the details that drive this projected value?

Result: Fair Value of $98.63 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing margin pressures and underperformance in key segments could limit Medtronic’s earnings growth, which may challenge the bullish analyst narrative if not addressed.

Find out about the key risks to this Medtronic narrative.

Build Your Own Medtronic Narrative

If you see things differently or want to dig deeper on your own terms, you can shape the Medtronic story for yourself in just a few minutes. Do it your way

A great starting point for your Medtronic research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Don’t let fresh market opportunities pass you by. The Simply Wall Street Screener is your shortcut to finding stocks that fit your boldest strategies and investing style.

• Fuel your portfolio with potential growth by starting your search among these 3568 penny stocks with strong financials, which are making headlines for robust financials and smart business pivots.
• Pinpoint generous income streams by scanning these 19 dividend stocks with yields > 3%, featuring companies paying attractive yields above 3% for steady returns.
• Target companies harnessing artificial intelligence in healthcare by checking these 31 healthcare AI stocks, where innovation is transforming patient care and industry dynamics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com